Dataset Information

Determination of the antimalarial drug piperaquine in small volume pediatric plasma samples by LC-MS/MS.

ABSTRACT: Determination of piperaquine (PQ) in pediatric plasma requires a method with a small sample volume.We report a sensitive LC-MS/MS method for quantitation of PQ with only 25 µl human plasma. Using a deuterated internal standard (PQ-d6), an analytical PFP column, APCI(+) as the ion source and MRM (535/288 for PQ and 541/294 for the IS) for detection, the method has a linear calibration range of 1.5-250 ng/ml with a runtime of 3.0 min per sample. The method was applied to plasma samples from children.The developed LC-MS/MS method is suitable for pediatric studies with small volume plasma samples collected via capillary tubes. One limitation was the performance of PFP columns varied among different brands.

SUBMITTER: Kjellin LL

PROVIDER: S-EPMC4321809 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Determination of the antimalarial drug piperaquine in small volume pediatric plasma samples by LC-MS/MS.

Kjellin Linda L LL Dorsey Grant G Rosenthal Philip J PJ Aweeka Francesca F Huang Liusheng L

Bioanalysis 20140101 23

<h4>Aim</h4>Determination of piperaquine (PQ) in pediatric plasma requires a method with a small sample volume.<h4>Results</h4>We report a sensitive LC-MS/MS method for quantitation of PQ with only 25 µl human plasma. Using a deuterated internal standard (PQ-d6), an analytical PFP column, APCI(+) as the ion source and MRM (535/288 for PQ and 541/294 for the IS) for detection, the method has a linear calibration range of 1.5-250 ng/ml with a runtime of 3.0 min per sample. The method was applied t ...[more]

PMID: 25529877

Similar Datasets

Project description:The emergence of novel drugs and the continuous expansion of the scope of the types of drugs under control have greatly increased requests for screening of a range of drugs in hair. Here, a multi-analyte method for the detection and quantification of 88 psychotropic drugs in the hair of addicts in drug abstinence was developed and fully validated using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Hair samples (25 mg) were washed, cut into pieces, cryogenically ground, and extracted in methanol. The extracted analytes were separated on an Allure PFPP column (100×2.1 mm, 5 mm i.d., Restek, USA) and analyzed by LC-MS/MS in multiple reaction monitoring mode. The limits of detection and limits of quantification ranged from 0.1 to 20 pg/mg and 0.2 to 50 pg/mg, respectively. The intra- and inter-assay precisions (RSD) of all analysis ranged from 0.9 to 14.9% and 1.9 to 15.9%, respectively. Accuracy values were 100±20%. The extraction recovery of quality control samples ranged from 50.9% to 99.6% for all analytes. The matrix effects for all analytes ranged from 46.8% to 99.7%. The method was successfully used to analyze 1,865 hair samples from addicts in drug rehabilitation at their own communities.. Among the samples, 129 cases were positive; the majority of positive cases were from males (78.29%), 92.25% of whom were over 35 years old. Traditional drugs, like methamphetamine and opioids, accounted for most positive cases, and 27 of the abstinence cases with a use history of methamphetamine were still positive. In addition to abused drugs, like methamphetamine, morphine, and cocaine, the sedative hypnotic and psychotherapeutic drugs, including clonazepam, alprazolam, estazolam, zolpidem, and quetiapine, were detected in 26% of the hair samples, suggesting that these addicts may have insomnia and mental problems such as depression and psychosis, probably due to the long-term effects of drugs and withdrawal reactions. Three synthetic cannabinoids were also detected in 4 (2.7%) cases. A total of 37 cases were positive for methadone, tramadol, and dextromethorphan, reflecting a new trend of alternative drug use when traditional drugs were not easy to obtain during the COVID-19 outbreak.

Project description:In recent years, therapeutic drug monitoring (TDM) has been applied in docetaxel (DOC)-based anticancer therapy to precisely control various pharmacokinetic parameters, including the concentration of DOC in biofluids (e.g., plasma or urine), its clearance, and its area under the curve (AUC). The ability to determine these values and to monitor DOC levels in biological samples depends on the availability of precise and accurate analytical methods that both enable fast and sensitive analysis and can be implemented in routine clinical practice. This paper presents a new method for isolating DOC from plasma and urine samples based on the coupling of microextraction and advanced liquid chromatography with tandem mass spectrometry (LC-MS/MS). In the proposed method, biological samples are prepared via ultrasound-assisted dispersive liquid-liquid microextraction (UA-DLLME) using ethanol (EtOH) and chloroform (Chl) as the desorption and extraction solvents, respectively. The proposed protocol was fully validated according to the Food and Drug Administration (FDA) and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) requirements. The developed method was then applied to monitor the DOC profile in plasma and urine samples collected from a pediatric patient suffering from cardiac angiosarcoma (AS) with metastasis to lungs and mediastinal lymph nodes, who was receiving treatment with DOC at a dose of 30 mg/m2 body surface area. Due to the rarity of this disease, TDM was carried out to determine the exact levels of DOC at particular time points to ascertain which levels were conducive to maximizing the treatment's effectiveness while minimizing the drug's toxicity. To this end, the concentration-time profiles of DOC in the plasma and urine samples were determined, and the levels of DOC at specific time intervals up to 3 days after administration were measured. The results showed that DOC was present at higher concentrations in the plasma than in the urine samples, which is due to the fact that this drug is primarily metabolized in the liver and then eliminated with the bile. The obtained data provided information about the pharmacokinetic profile of DOC in pediatric patients with cardiac AS, which enabled the dose to be adjusted to achieve the optimal therapeutic regimen. The findings of this work demonstrate that the optimized method can be applied for the routine monitoring of DOC levels in plasma and urine samples as a part of pharmacotherapy in oncological patients.

Dataset Information

Determination of the antimalarial drug piperaquine in small volume pediatric plasma samples by LC-MS/MS.

Publications

Determination of the antimalarial drug piperaquine in small volume pediatric plasma samples by LC-MS/MS.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets